958888-27-2

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Dihydroxy-5-isopropylbenzaldehyde is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Fragrance Industry:
In the fragrance industry, 2,4-Dihydroxy-5-isopropylbenzaldehyde is used as a raw material for creating unique scents, capitalizing on its chemical structure to produce novel fragrance compounds.
Used in Organic Compounds Synthesis:
2,4-Dihydroxy-5-isopropylbenzaldehyde serves as a versatile building block in the synthesis of various organic compounds, facilitating the creation of a wide range of chemical products.
Used as Antioxidant:
2,4-Dihydroxy-5-isopropylbenzaldehyde is used as an antioxidant in various applications, leveraging its ability to combat oxidative stress and protect against damage caused by reactive oxygen species.
Used as Antiseptic:
2,4-Dihydroxy-5-isopropylbenzaldehyde is utilized as an antiseptic due to its antibacterial properties, making it suitable for use in sanitizing solutions and products to prevent infection.
Used in Flavoring Agents:
It is employed in the production of flavoring agents, where its unique chemical structure contributes to the development of distinct tastes in food and beverage products.
Used in Medicine:
2,4-Dihydroxy-5-isopropylbenzaldehyde has potential applications in medicine, where its properties can be harnessed for the treatment of various conditions, including its use in the development of new pharmaceuticals.
Used in Agriculture:
In agriculture, the compound may be used for its antibacterial properties to protect crops from bacterial infections, contributing to increased crop yields and food security.
Used in Materials Science:
2,4-Dihydroxy-5-isopropylbenzaldehyde's unique structure and functional groups make it a candidate for use in materials science, where it could be employed in the development of new materials with specific properties for various applications.

Upstream product

• 1155371-80-4 (((4-isopropyl-1,3-phenylene)bis(oxy))bis(methylene))dibenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 1155371-78-0 2-(2,4-bis(benzyloxy)phenyl)propan-2-ol 
• 23504-03-2 2,4-dihydroxy-1-isopropylbenzene 
• 22877-01-6 2,4-bis(benzyloxy)acetophenone 
• 747414-16-0 (((4-(prop-1-en-2-yl)-1,3-phenylene)bis(oxy))bis(methylene))dibenzene 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 

Downstream Products

• 959466-51-4 2,4-bis(benzyloxy)-5-isopropylbenzaldehyde 
• 958888-26-1 5-(2,4-bis(benzyloxy)-5-isopropylphenyl)-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazole-3-ol 
• 888216-25-9 5-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-2,4-dihydro-4-(1-methyl-1H-indol-5-yl)-3H-1,2,4-triazole-3-one 
• 958888-26-1 C₃₄H₃₂N₄O₃ 
• 1071151-44-4 5-isopropyl-2,4-dimethoxybenzaldehyde 

Relevant academic research and scientific papers

A tumor-targeted Ganetespib-zinc phthalocyanine conjugate for synergistic chemo-photodynamic therapy

Therapeutic effects of photodynamic therapy (PDT) are limited by the selectivity of photosensitizer (PS). Herein, a novel tumor-targeted drug-PS conjugate (Gan-ZnPc) which integrated with zinc phthalocyanine (ZnPc) and Ganetespib has been developed. ZnPc is a promising PS with remarkable photosensitization ability. Ganetespib is a heat shock protein 90 (Hsp90) inhibitor with preferential tumor selectivity and conjugated to ZnPc as a tumor-targeted ligand. The multifunctional small molecule conjugate, Gan-ZnPc, could be bound to extracellular Hsp90 and then selectively internalized into the tumor cells, followed by the generation of abundant intracellular reactive oxygen species (ROS) upon irradiation. Besides, Gan-ZnPc can arrest cell proliferation and induce apoptosis by the inhibition of Hsp90. Herein, with combination of the inhibition of Hsp90 and the generation of cytotoxic ROS, Gan-ZnPc implements tumor selectivity, concentrated PDT and chemotherapy in a synergistic manner, which results in highly effective anti-tumor activity in vitro and in vivo.

HEAT SHOCK PROTEIN 90 INHIBITORS

Substituted aromatic compounds of formula (I) shown below: (formula I) The definition of each variable in formula (I) appears in the Specification. Also disclosed is a pharmaceutical composition containing one of the substituted aromatic compounds. Further disclosed is a method of using one of these compounds for treating a medical condition associated with HSP90.

Improved method for preparing HSP90 inhibitor Ganetespib

The invention discloses an improved method for preparing an HSP90 inhibitor Ganetespib. According to the method, raw materials in the synthesizing method are improved, certain raw materials with relatively high prices are subjected to designing synthesis

Triazole derivative having HSP90 (Heat Shock Protein) inhibiting activity, as well as preparation method and application of triazole derivative

The invention discloses a triazole derivative having an HSP90 (Heat Shock Protein) inhibiting activity, as well as a preparation method and an application of the triazole derivative. Specifically, the invention relates to the triazole derivative having a structure as shown in a formula (I), a stereisomer of the triazole derivative and a pharmaceutically acceptable salt, wherein the definition of each substituent group in the formula (I) and the definition in a description are the same. The compound with a novel structure has the HSP90 inhibiting activity, can be used to cure cancers, neurodegenerative disorders, inflammation diseases, autoimmune diseases, ischemic brain injuries and the like, and has a broad application prospect.

Phenyl 1, 2 - isoxazole or phenyl 1, 2 - pyrazole compound and use thereof (by machine translation)

The invention discloses the following formula of phenyl 1, 2 - different oxazole or 1, 2 - pyrazole compounds with use. Through the biological activity tests show that, the compound inhibiting heat shock protein 90 activity. Therefore, the invention phenyl 1, 2 - different oxazole or 1, 2 - pyrazole compounds can be used as a heat shock protein 90 inhibitor for the treatment of cancer. (by machine translation)

Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors

HSP90 is ubiquitously overexpressed in a broad spectrum of human cancers and has been recognized as an attractive target for cancer treatment. Here, we described the fragment screening, synthesis and structure-activity relationship studies of small molecule inhibitors with 4,5-diarylisoxazole scaffold targeting HSP90. Among them, the compound N-(3-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-((4-morpholinopiperidin-1-yl)methyl)phenyl)isoxazol-5-yl)cyclopropanecarboxamide (108) showed high affinity for binding to HSP90 (FP binding assay, IC50 Combining double low line 0.030 μM) and inhibited the proliferation of various human cancer cell lines with averaging GI50 about 88 nM. Compound 108 exhibited its functional inhibition of HSP90 by depleting key signaling pathways and concomitantly elevating of HSP70 and HSP27 in U-87MG cells. Further in vivo studies showed that compound 108 strongly suppressed the tumor growth of human glioblastoma xenograft model U-87MG with T/C Combining double low line 18.35% at 50 mg/kg q3w/2.5w. Moreover, compound 108 also exhibited good pharmacokinetic properties. Together, our study implicates that compound 108 is a promising candidate of HSP90 inhibitor and is currently advanced to preclinical study.

METHOD FOR TREATING INFLAMMATORY DISORDERS

The present invention relates to a method for suppressing the immune system in a subject in need thereof, and a method for treating an inflammatory or immune disorder in a subject in need thereof.

Synthesis of triazole compounds that modulate HSP90 activity

The present invention provides novel methods of preparing triazole compounds which inhibit the activity of Hsp90. One embodiment of the invention is directed to methods for preparing a triazole compound represented by the following Structural Formula: or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising the steps of: a) reacting an amide represented by the following Structural Formula: with a thionation reagent to form a thioamide; b) reacting the thioamide of step a) with hydrazine to form a hydrazonamide; c) reacting the hydrazonamide of step b) with a carbonylation or a thiocarbonylation reagent. In one embodiment, the present invention is a method of synthesis of a compound of formula (IA) or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising reacting a compound of formula (IIA) with an oxidizing agent, thereby producing a compound of formula (IA). The present invention is also directed to a method of preparing a compound or a tautomer thereof represented by the following Structural Formula: or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof. The method comprises the step of reacting a first starting compound represented by the following Structural Formula: in the presence of a mercuric salt, with a second starting compound represented by the following Structural Formula:

METHOD FOR TREATING INFECTIONS

The present invention relates to compounds that inhibit the activity of Hsp90 and methods of using these compounds for treating or preventing infection.

METHOD FOR INHIBITING TOPOISOMERASE II

The present invention relates to compounds that inhibit the activity of Hsp90 and inhibit topoisomerase II.